Fig. 3: DRPs in human and murine MASLD.
Selection of KEGG-affected pathways characterizing the ‘early disease development’, ‘all disease stages’ and ‘disease progression’ groups. The ‘early disease development’ group includes statistically significant (P < 0.05) modulated pathways in ‘mild vs controls’ but not in ‘moderate–severe vs mild’ human disease stages comparisons. The ‘all disease stages’ group includes statistically significant and homogeneously modulated pathways at all human disease stages (‘mild vs controls’ and ‘moderate–severe vs mild’ in both UCAM–VCU and EPoS); the ‘disease progression’ group includes homogeneously modulated and statistically significant pathways in ‘moderate–severe vs mild’ comparisons in both UCAM–VCU and EPoS but not in ‘mild vs controls’ comparisons. FGSEA calculated a normalized enrichment score (NES; the enrichment score normalized to mean enrichment of random samples of the same size) for each pathway and determined statistical significance using permutation testing (two-sided), adjusting for multiple comparisons to control the false discovery rate (FDR). The human and murine datasets are represented in a color-scale matrix showing the NES. * and $ symbols denote statistical significance ($, P < 0.05; *, FDR < 0.05). All models are grouped according to their macro-categories, as indicated by the panel on the top of the heatmap.
